Cargando…

Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia

BACKGROUND: Interrogate the impact of IKZF1 deletion on therapy-outcomes of adults with common B-cell acute lymphoblastic leukemia. METHODS: One hundred sixty-five consecutive adults with common B-cell ALL were tested for IKZF1 deletion and for BCR/ABL. Deletions in IKZF1 were detected using multipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Qiu-Mei, Liu, Kai-Yan, Gale, Robert Peter, Jiang, Bin, Liu, Yan-Rong, Jiang, Qian, Jiang, Hao, Zhang, Xiao-Hui, Zhang, Mei-Jie, Chen, Shan-Shan, Huang, Xiao-Jun, Xu, Lan-Ping, Ruan, Guo-Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828764/
https://www.ncbi.nlm.nih.gov/pubmed/27067989
http://dx.doi.org/10.1186/s12885-016-2300-7
_version_ 1782426643275448320
author Yao, Qiu-Mei
Liu, Kai-Yan
Gale, Robert Peter
Jiang, Bin
Liu, Yan-Rong
Jiang, Qian
Jiang, Hao
Zhang, Xiao-Hui
Zhang, Mei-Jie
Chen, Shan-Shan
Huang, Xiao-Jun
Xu, Lan-Ping
Ruan, Guo-Rui
author_facet Yao, Qiu-Mei
Liu, Kai-Yan
Gale, Robert Peter
Jiang, Bin
Liu, Yan-Rong
Jiang, Qian
Jiang, Hao
Zhang, Xiao-Hui
Zhang, Mei-Jie
Chen, Shan-Shan
Huang, Xiao-Jun
Xu, Lan-Ping
Ruan, Guo-Rui
author_sort Yao, Qiu-Mei
collection PubMed
description BACKGROUND: Interrogate the impact of IKZF1 deletion on therapy-outcomes of adults with common B-cell acute lymphoblastic leukemia. METHODS: One hundred sixty-five consecutive adults with common B-cell ALL were tested for IKZF1 deletion and for BCR/ABL. Deletions in IKZF1 were detected using multiplex RQ-PCR, multiplex fluorescent PCR, sequence analysis and multiplex ligation-dependent probe amplification (MLPA). BCR/ABL was detected using RQ-PCR. All subjects received chemotherapy and some also received an allotransplant and tyrosine kinase-inhibitors. Multivariate analyses were done to identify associations between IKZF1 deletion and other variables on non-relapse mortality (NRM), cumulative incidence of relapse (CIR), leukemia-free survival (LFS) and survival. RESULTS: Amongst subjects achieving complete remission those with IKZF1 deletion had similar 5-year non-relapse mortality (NRM) (11 % [2–20 %] vs. 16 % [4–28 %]; P = 0.736), a higher 5-year cumulative incidence of relapse (CIR) (55 % [35–76 %] vs. 25 % [12–38 %]; P = 0.004), and worse 5-year leukemia-free survival (LFS) (33 % [16–52 %] vs. 59 % [42–73 %]; P = 0.012) and survival (48 % [33–62 %] vs. 75 % [57–86 %]; P = 0.002). In multivariate analyses IKZF1 deletion was associated with an increased relapse (relative risk [RR] =2.7, [1.4–5.2]; P = 0.002), a higher risk of treatment-failure (inverse of LFS; RR = 2.1, [1.2–3.6]; P = 0.007) and a higher risk of death (RR = 2.8, [1.5–5.5]; P = 0.002). The adverse impact of IKZF1 deletion on outcomes was stronger in subjects without vs. with BCR-ABL1 and in subjects receiving chemotherapy-only vs. an allotransplant. CONCLUSIONS: IKZF1 deletion was independently-associated with a higher relapse risk and worse LFS and survival in adults with common B-cell ALL after adjusting for other prognostic variables and differences in therapies. These data suggest IKZF1 deletion may be a useful prognostic variable in adults with common B-cell ALL, especially in persons without BCR-ABL1 and those receiving chemotherapy-only. Transplants appear to overcome the adverse impact of IKZF1 deletion on therapy-outcomes but confirmation in a randomized study is needed. The trial was registered in 2007 with the Beijing Municipal Government (Beijing Municipal Health Bureau Registration N: 2007–1007).
format Online
Article
Text
id pubmed-4828764
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48287642016-04-13 Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia Yao, Qiu-Mei Liu, Kai-Yan Gale, Robert Peter Jiang, Bin Liu, Yan-Rong Jiang, Qian Jiang, Hao Zhang, Xiao-Hui Zhang, Mei-Jie Chen, Shan-Shan Huang, Xiao-Jun Xu, Lan-Ping Ruan, Guo-Rui BMC Cancer Research Article BACKGROUND: Interrogate the impact of IKZF1 deletion on therapy-outcomes of adults with common B-cell acute lymphoblastic leukemia. METHODS: One hundred sixty-five consecutive adults with common B-cell ALL were tested for IKZF1 deletion and for BCR/ABL. Deletions in IKZF1 were detected using multiplex RQ-PCR, multiplex fluorescent PCR, sequence analysis and multiplex ligation-dependent probe amplification (MLPA). BCR/ABL was detected using RQ-PCR. All subjects received chemotherapy and some also received an allotransplant and tyrosine kinase-inhibitors. Multivariate analyses were done to identify associations between IKZF1 deletion and other variables on non-relapse mortality (NRM), cumulative incidence of relapse (CIR), leukemia-free survival (LFS) and survival. RESULTS: Amongst subjects achieving complete remission those with IKZF1 deletion had similar 5-year non-relapse mortality (NRM) (11 % [2–20 %] vs. 16 % [4–28 %]; P = 0.736), a higher 5-year cumulative incidence of relapse (CIR) (55 % [35–76 %] vs. 25 % [12–38 %]; P = 0.004), and worse 5-year leukemia-free survival (LFS) (33 % [16–52 %] vs. 59 % [42–73 %]; P = 0.012) and survival (48 % [33–62 %] vs. 75 % [57–86 %]; P = 0.002). In multivariate analyses IKZF1 deletion was associated with an increased relapse (relative risk [RR] =2.7, [1.4–5.2]; P = 0.002), a higher risk of treatment-failure (inverse of LFS; RR = 2.1, [1.2–3.6]; P = 0.007) and a higher risk of death (RR = 2.8, [1.5–5.5]; P = 0.002). The adverse impact of IKZF1 deletion on outcomes was stronger in subjects without vs. with BCR-ABL1 and in subjects receiving chemotherapy-only vs. an allotransplant. CONCLUSIONS: IKZF1 deletion was independently-associated with a higher relapse risk and worse LFS and survival in adults with common B-cell ALL after adjusting for other prognostic variables and differences in therapies. These data suggest IKZF1 deletion may be a useful prognostic variable in adults with common B-cell ALL, especially in persons without BCR-ABL1 and those receiving chemotherapy-only. Transplants appear to overcome the adverse impact of IKZF1 deletion on therapy-outcomes but confirmation in a randomized study is needed. The trial was registered in 2007 with the Beijing Municipal Government (Beijing Municipal Health Bureau Registration N: 2007–1007). BioMed Central 2016-04-11 /pmc/articles/PMC4828764/ /pubmed/27067989 http://dx.doi.org/10.1186/s12885-016-2300-7 Text en © Yao et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yao, Qiu-Mei
Liu, Kai-Yan
Gale, Robert Peter
Jiang, Bin
Liu, Yan-Rong
Jiang, Qian
Jiang, Hao
Zhang, Xiao-Hui
Zhang, Mei-Jie
Chen, Shan-Shan
Huang, Xiao-Jun
Xu, Lan-Ping
Ruan, Guo-Rui
Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia
title Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia
title_full Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia
title_fullStr Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia
title_full_unstemmed Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia
title_short Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia
title_sort prognostic impact of ikzf1 deletion in adults with common b-cell acute lymphoblastic leukemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828764/
https://www.ncbi.nlm.nih.gov/pubmed/27067989
http://dx.doi.org/10.1186/s12885-016-2300-7
work_keys_str_mv AT yaoqiumei prognosticimpactofikzf1deletioninadultswithcommonbcellacutelymphoblasticleukemia
AT liukaiyan prognosticimpactofikzf1deletioninadultswithcommonbcellacutelymphoblasticleukemia
AT galerobertpeter prognosticimpactofikzf1deletioninadultswithcommonbcellacutelymphoblasticleukemia
AT jiangbin prognosticimpactofikzf1deletioninadultswithcommonbcellacutelymphoblasticleukemia
AT liuyanrong prognosticimpactofikzf1deletioninadultswithcommonbcellacutelymphoblasticleukemia
AT jiangqian prognosticimpactofikzf1deletioninadultswithcommonbcellacutelymphoblasticleukemia
AT jianghao prognosticimpactofikzf1deletioninadultswithcommonbcellacutelymphoblasticleukemia
AT zhangxiaohui prognosticimpactofikzf1deletioninadultswithcommonbcellacutelymphoblasticleukemia
AT zhangmeijie prognosticimpactofikzf1deletioninadultswithcommonbcellacutelymphoblasticleukemia
AT chenshanshan prognosticimpactofikzf1deletioninadultswithcommonbcellacutelymphoblasticleukemia
AT huangxiaojun prognosticimpactofikzf1deletioninadultswithcommonbcellacutelymphoblasticleukemia
AT xulanping prognosticimpactofikzf1deletioninadultswithcommonbcellacutelymphoblasticleukemia
AT ruanguorui prognosticimpactofikzf1deletioninadultswithcommonbcellacutelymphoblasticleukemia